Early-stage funding for European life sciences companies

We are a venture capital firm specialised in seed investment for innovative early stage companies. BGV generally acts as lead investor. Our current portfolio comprises of biotech developing truly disruptive solutions for high unmet medical needs.

Acerta, a multi-billion Euro success story

BioGeneration was co-founder and investor in the most successful biotech startup in Europe: Acerta Pharma. Acerta Pharma has developed Calquence® (acalabrutinib), a drug now approved by the FDA for the treatment of hematologic malignancies (leukemia). Acerta was sold to AstraZeneca for up to US$ 7 billion in 2016.

Shaping new life-science ventures

We gained our experience from working within small and large pharma and biotech companies. Based on this experience and through our extensive industry network, we are able to bring a range of sector-relevant expertise to help accelerate product development and shape the companies to become attractive investment opportunities for the industry.

Latest news

FIRST Fund: PHLOX THERAPEUTICS CLOSES SEED INVESTMENT ROUND

May 16, 2022

16 May 2020, Naarden, The Netherlands - Phlox Therapeutics, a biotech spin-off of the Amsterdam University Medical Center founded by prof. dr. Yigal Pinto and prof. dr. Eva van Rooij, with Margien Boels, PhD as its initiating director of operations have announced the...

BGV Fellowship

Apr 14, 2022

Location: Naarden, The Netherlands Duration: 6-9 months About BGV Since our inception in 2006, BGV has raised four early-stage biotech funds totaling over €250 million in capital. Our portfolio is focused on novel therapeutics across different treatment modalities and...

Scenic Biotech and the Barth Syndrome Foundation Announce
Partnership to Explore Genetic Modifiers to a Find Tailored
Treatment for the Complex Rare Disease

Mar 30, 2022

Amsterdam, The Netherlands, and Boston, MA, USA - 30 March 2022 - Scenic Biotech BV (‘Scenic’ or ‘the Company’), a pioneer in the discovery of genetic modifiers to enable the development of disease modifying therapeutics for rare genetic disorders and other...

Azafaros Announces FDA Grant of Orphan Drug Designation for AZ-3102 in the Treatment of Niemann-Pick Disease

Mar 24, 2022

- Second Orphan Drug Designation Supports Azafaros’ Strategy to Develop AZ-3102 as a Disease Modifying Treatment in a Range of Severe Rare Inherited Metabolic Disorders – Leiden, The Netherlands, March 24, 2022 – Azafaros B.V. today announced that the US Food and Drug...

News overview

Next events

BioVaria 11-12 May

May 2, 2022

BioVaria targets technology scouts, business developers and investors highlighting commercially attractive licensing opportunities and promising startups from across Europe. This unique event brings together Europe‘s leading tech transfer professionals, innovators...

Institutional Investment and Venture Capital in The Netherlands 10 May

Apr 26, 2022

Dutch Venture Capital is gaining momentum. However, the data shows that Dutch (and European) institutional investors remain underexposed to the Venture Capital asset class relative to their US or Chinese counterparts. On 10 May, BGV Managing Partner Edward van...

Venture Challenge 22 April, 2022

Apr 19, 2022

FIRST Fund's Rianne Ellenbroek joins the jury for Venture Challenge taking place on 22 April 2022 in Den Haag. During the Venture Challenge, researchers are guided in setting up a venture plan, in which a scientific breakthrough in the life sciences is converted into...

Event overview